Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929023 | 0.93 | CFB (0.43) | CFBCYP3A4CYP2D6KCNH2PARP1 | |
| SCHEMBL5929015 | 0.93 | CFB (0.50) | CFBCYP3A4CYP2D6KCNH2PARP1 | |
| SCHEMBL5929089 | 0.93 | CFB (0.43) | CFBCYP3A4CYP2D6KCNH2HTR4 | |
| SCHEMBL5929025 | 0.89 | CFB (0.37) | CFBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5928944 | 0.85 | PARP1 (0.42) | CFBCYP3A4CYP2D6KCNH2PARP1 | |
| SCHEMBL5929301 | 0.84 | KDM4E (0.39) | CFBCYP3A4CYP2D6KCNH2OPRK1 | |
| SCHEMBL5929052 | 0.84 | KDM4E (0.39) | CFBCYP3A4CYP2D6KCNH2OPRK1 | |
| SCHEMBL5928941 | 0.84 | KDM4E (0.39) | CFBCYP3A4CYP2D6KCNH2OPRK1 | |
| SCHEMBL5929004 | 0.83 | KMT2A (0.39) | CFB | |
| SCHEMBL5929140 | 0.83 | SMN1; SMN2 (0.38) | CFBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2005007087-A2 | SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | CFB 26/4885CYP3A4 983/4885CYP2D6 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.